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Introduction
Few data are available on the pharmacokinetics (PKs) of
b-lactams in critically ill cirrhotic patients.
Objectives
The objective of this study was to evaluate whether cir-
rhosis was associated with alterations in b-lactam con-
centrations when compared to other critically ill
patients, and to identify the principal risk factors for
inadequate concentrations in these patients.
Methods
We reviewed data from critically ill cirrhotic patients and
matched controls in whom routine therapeutic drug moni-
toring (TDM) of broad-spectrum b-lactam antibiotics (cef-
tazidime or cefepime, CEF; piperacillin/tazobactam; TZP;
meropenem, MEM) was performed. Serum drug concen-
trations were measured twice during the elimination phase
by high-performance liquid chromatography (HPLC-UV).
Antibiotic PKs were calculated using a one-compartment
model. We considered therapy was adequate when serum
drug concentrations were between 4 and 8 times the mini-
mal inhibitory concentration (MIC) of Pseudomonas aeru-
ginosa during optimal periods of time for each drug (≥70%
for CEF; ≥ 50% for TZP; ≥ 40% for MEM).
Results
We studied 42 cirrhotic patients (4 for CEF, 16 for TZP
and 22 for MEM) and 42 matched controls. Drug dosing
was similar in the two groups. The PK analysis showed a
lower volume of distribution (Vd) of MEM (p = 0.05) and
a lower antibiotic clearance (CL) of TZP (p = 0.009) in
patients with cirrhosis when compared to non-cirrhotic
patients. More cirrhotic patients have excessive serum
b-lactam concentration (p = 0.015), in particular for TZP.
Conclusions
Standard regimens of b-lactam resulted in excessive
serum concentration in two-third of the patients in the
cirrhotic cohort. These findings are mainly marked in cir-
rhotic patients treated by TZP, probably because of
reduced drug CL.
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